Document Detail

Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale.
MedLine Citation:
PMID:  3938395     Owner:  NLM     Status:  MEDLINE    
The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1). After one week, prazosin reduced mean pulmonary artery pressure and pulmonary and systemic vascular resistance, and increased cardiac index both at rest and during exercise. Similarly improved haemodynamics were observed after two months of therapy. Arterial PO2 and oxygen saturation fell significantly after two months both at rest and during exercise, but were not changed after one week. Lung function tests were not altered by prazosin. Thus, although prazosin improves the haemodynamics in patients with chronic obstructive lung disease, caution is advised in long-term therapy since prazosin worsens the arterial blood oxygenation.
H Vik-Mo; N Walde; H Jentoft; F J Halvorsen
Related Documents :
1586045 - Treatment of pulmonary arteriovenous malformations by therapeutic embolization. rest an...
20412435 - Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs.
8436745 - Pulmonary and peripheral vascular factors are important determinants of peak exercise o...
8417905 - Unilateral absence of a pulmonary artery. data from cardiopulmonary exercise testing.
24088865 - Analysis of pushing exercises: muscle activity and spine load while contrasting techniq...
20538225 - The efficacy of frequency specific microcurrent therapy on delayed onset muscle soreness.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European heart journal     Volume:  6     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1985 Dec 
Date Detail:
Created Date:  1986-05-07     Completed Date:  1986-05-07     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1047-53     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Carbon Dioxide / blood
Chronic Disease
Hemodynamics / drug effects*
Hypertension, Pulmonary / complications
Lung / physiopathology
Lung Diseases, Obstructive / complications
Middle Aged
Oxygen / blood*
Physical Exertion*
Prazosin / administration & dosage,  pharmacology*,  therapeutic use
Pulmonary Heart Disease / drug therapy,  etiology,  physiopathology*
Reg. No./Substance:
124-38-9/Carbon Dioxide; 19216-56-9/Prazosin; 7782-44-7/Oxygen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Metabolism of aromatic amines by prostaglandin H synthase.
Next Document:  Mitomycin C and vinblastine in the treatment of advanced breast cancer.